New weight loss injection BGM1812 enters human testing
NCT ID NCT07224399
First seen Nov 05, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-stage study tests a new drug called BGM1812 in 60 overweight or obese but otherwise healthy adults. The goal is to check the drug's safety, how the body processes it, and whether it leads to weight loss. Participants receive either the drug or a placebo injection under the skin, and researchers monitor side effects and changes in body weight over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pharmaron CPC, Inc
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.